Abstract
The emergence of multidrug-resistant (MDR) pathogens has escalated the global need for novel antimicrobial strategies. Antimicrobial peptides (AMPs), naturally occurring molecules found in a wide range of organisms, offer a promising alternative to conventional antibiotics. Their unique modes of action, including membrane disruption and immune modulation, make them potent candidates for combating resistant microbes. This article reviews the development of AMPs as therapeutic agents, their mechanisms, challenges in clinical translation, and recent advances in peptide engineering to enhance efficacy and stability. The potential of AMPs to serve as a cornerstone in future antimicrobial therapy is significant, though regulatory and formulation hurdles remain.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.